BC Innovations | Aug 23, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Malaria Cell culture and mouse studies identified an inhibitor of P. falciparum proteasome subunit β type 2 and proteasome subunit β type 5 that could help treat malaria. Chemical synthesis and testing of vinyl...
BC Week In Review | Aug 17, 2015
Company News

Sigma-Tau, Pierre Fabre Group deal

Sigma-Tau granted Pierre Fabre an exclusive license to commercialize Eurartesim in 32 African countries. The antimalarial combination of dihydroartemisinin and piperaquine is approved in Europe and several of the countries covered by the deal. Pierre...
BC Extra | Aug 7, 2014
Clinical News

Continuous treatment reduces malaria risk in young children

Researchers at the University of California , San Francisco, published data showing that Ugandan children 6 to 24 months of age at risk of contracting malaria were 58% less likely to develop malaria when receiving monthly...
BC Innovations | Dec 19, 2013
Targets & Mechanisms

Lipid kinase enters the malaria stage

A Novartis AG - University of California, San Diego -led consortium has identified a new class of antimalarials that, unlike marketed drugs, eliminates Plasmodium at all stages of its infection cycle. 1 The pharma is developing...
BC Innovations | Apr 25, 2013
Distillery Techniques

Technology: Chemistry

Approach Summary Licensing status Publication and contact information Chemistry Semisynthetic synthesis of artemisinin Biological production of artemisinic acid and chemical conversion of the acid to artemisinin could help supply first-line treatments for malaria infection at...
BC Week In Review | Jul 16, 2012
Company News

Sigma-Tau sales and marketing update

Sigma-Tau launched Eurartesim dihydroartemisinin/piperaquine in France, Germany, Belgium, Portugal and the U.K. to treat uncomplicated malaria. The company also said the product is now ready for delivery to Cambodia. The antimalarial combination of dihydroartemisinin and...
BC Week In Review | Dec 5, 2011
Clinical News

Eurartesim dihydroartemisinin/piperaquine regulatory update

The European Commission approved Eurartesim dihydroartemisinin/piperaquine from Sigma-Tau to treat uncomplicated Plasmodium falciparum malaria. The fixed combination of dihydroartemisinin and piperaquine is being co-developed with Medicines for Malaria Venture (Geneva, Switzerland). Eurartesim has Orphan Drug...
BC Extra | Dec 1, 2011
Company News

Eurartesim approved in Europe

The European Commission approved Eurartesim dihydroartemisinin/piperaquine from Sigma-Tau Group (Pomezia, Italy) to treat uncomplicated Plasmodium falciparum malaria. The combination was co-developed with Medicines for Malaria Venture....
BC Week In Review | Jun 27, 2011
Clinical News

Euratesim dihydroartemisinin/piperaquine regulatory update

EMA's CHMP issued a positive opinion recommending approval of an MAA for Eurartesim dihydroartemisinin/piperaquine from Sigma-Tau to treat uncomplicated Plasmodium falciparum malaria in adults, children and infants >=6 months. The compound is being co-developed with...
BC Extra | Jun 25, 2011
Company News

CHMP backs Vectibix, Trajenta, Eurartesim

EMA's CHMP issued several positive opinions on Friday, including a reversal of a prior decision for Vectibix panitumumab from Amgen Inc. (NASDAQ:AMGN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). CHMP recommended expanding the label of the...
Items per page:
1 - 10 of 22